0000000000611795

AUTHOR

Marco Confalonieri

showing 10 related works from this author

Complement Protein C1q Binds to Hyaluronic Acid in the Malignant Pleural Mesothelioma Microenvironment and Promotes Tumor Growth

2017

C1q is the first recognition subcomponent of the complement classical pathway, which acts towards the clearance of pathogens and apoptotic cells. C1q is also known to modulate a range of functions of immune and non-immune cells, including their involvement in placental development and sensorial synaptic pruning. We have recently shown that C1q can promote tumour by encouraging their adhesion, migration and proliferation in addition to angiogenesis and metastasis. In this study, we have examined the role of C1q in the microenvironment of malignant pleuric mesothelioma (MPM), a rare form of cancer commonly associated with exposure to asbestos. We found that C1q was highly expressed in all MPM…

lcsh:Immunologic diseases. Allergy0301 basic medicineComplement system; Malignant pleural mesothelioma; Hyaluronic acid; Mesothelioma cells; C1q; CancerAngiogenesisMPMp38 mitogen-activated protein kinasesImmunologyHAchemical and pharmacologic phenomenaBiologyMetastasisMesothelioma cell03 medical and health sciencesClassical complement pathwaychemistry.chemical_compound0302 clinical medicineImmune systemhyaluronic acidHyaluronic acidmedicinemalignant pleural mesotheliomacancerImmunology and AllergyCell adhesioncomplement systemC1qcomplement system; MPM; HA; Mesothelioma cells; C1q and cancerOriginal ResearchC1q and cancermedicine.diseaseComplement system030104 developmental biologyC1q; Cancer; Complement system; Hyaluronic acid; Malignant pleural mesothelioma; Mesothelioma cells; Immunology and Allergy; Immunologychemistrymesothelioma cells030220 oncology & carcinogenesisImmunologyCancer researchlcsh:RC581-607Frontiers in Immunology
researchProduct

C1q–Ha matrix regulates the local synthesis of hyaluronan in malignant pleural mesothelioma by modulating has3 expression

2021

Increased hyaluronic acid (HA) production is often associated with cancer progression. In malignant pleural mesothelioma (MPM), HA is found at elevated levels in pleural effusions and sera of patients, and it has been widely debated whether MPM cells are able to produce HA by themselves or through the release of growth factors stimulating other cells. Another key component of the MPM microenvironment is C1q, which can act as a pro-tumorigenic factor favoring cell adhesion, migration and proliferation. The aim of the current study was to prove that MPM primary cells are able to synthesize HA and to inquire the stimulus given by C1q&ndash

hyaluronan synthaseCancer ResearchComplement systemHyaluronic acidMalignant pleural mesotheliomahyaluronan synthasesMatrix (biology)lcsh:RC254-282Articlechemistry.chemical_compoundImmune systemHyaluronan synthaseHyaluronic acidhyaluronic acidmalignant pleural mesotheliomacancertumor microenvironmentC1q; Cancer; Complement system; HAS3; Hyaluronan synthases; Hyaluronic acid; Immune system; Malignant pleural mesothelioma; Tumor microenvironmenttumor microenvironment.Cell adhesioncomplement systemC1qCancerTumor microenvironmentMessenger RNAChemistrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensComplement systemimmune systemHAS3Immune systemOncologyTumor microenvironmentCancer researchIntracellular
researchProduct

Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study

2018

This study aimed to describe real-life microbiological testing of adults hospitalised with community-acquired pneumonia (CAP) and to assess concordance with the 2007 Infectious Diseases Society of America (IDSA)/American Thoracic Society (ATS) and 2011 European Respiratory Society (ERS) CAP guidelines. This was a cohort study based on the Global Initiative for Methicillin-resistant Staphylococcus aureus Pneumonia (GLIMP) database, which contains point-prevalence data on adults hospitalised with CAP across 54 countries during 2015. In total, 3702 patients were included. Testing was performed in 3217 patients, and included blood culture (71.1%), sputum culture (61.8%), Legionella urinary anti…

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtycommunity-acquired pneumoniaCommunity-acquired pneumoniaPatients4Concordance030106 microbiologyRespiratory Systemlcsh:MedicineSettore MED/10 - Malattie Dell'Apparato RespiratorioGUIDELINESPneumònia adquirida a la comunitatSputum cultureSerology03 medical and health sciences0302 clinical medicineCommunity-acquired pneumoniaInternal medicinemedicineMANAGEMENTBlood culture030212 general & internal medicinePOPULATIONpneumonia Methicillin-resistant Staphylococcus aureus PneumoniaScience & Technologymedicine.diagnostic_testbusiness.industryMORTALITYlcsh:RMicrobiologia mèdicaOriginal ArticlesGuidelinePneumoniaMedical microbiologymedicine.diseaseMicrobiologicalETIOLOGYPneumoniaDiagnostic testingREQUIRING HOSPITALIZATIONbusinessLife Sciences & BiomedicineCohort studyERJ Open Research
researchProduct

Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia

2021

Background: Aspiration community-acquired pneumonia (ACAP) and community-acquired pneumonia (CAP) in patients with aspiration risk factors (AspRFs) are infections associated with anaerobes, but limited evidence suggests their pathogenic role. Research Question: What are the aspiration risk factors, microbiology patterns, and empiric anti-anaerobic use in patients hospitalized with CAP? Study Design and Methods: This is a secondary analysis of GLIMP, an international, multicenter, point-prevalence study of adults hospitalized with CAP. Patients were stratified into three groups: (1) ACAP, (2) CAP/AspRF+ (CAP with AspRF), and (3) CAP/AspRF- (CAP without AspRF). Data on demographics, comorbidi…

MalePulmonary and Respiratory Medicinemedicine.drug_classAspiration riskAntibioticsNursing home residentSettore MED/10 - Malattie Dell'Apparato RespiratorioCritical Care and Intensive Care MedicineMicrobiologyanaerobic; aspiration; bacteria; pneumonia; risk factors.Cohort Studies03 medical and health sciences0302 clinical medicineCommunity-acquired pneumoniaTaverneAnti-Bacterial AgentmedicineHumanspneumoniarisk factors.Community-Acquired Infection030212 general & internal medicinebacteriaStrokeAgedAged 80 and overaspirationbusiness.industryRespiratory AspirationMiddle Agedmedicine.diseaseAntibiotic coverageAnti-Bacterial AgentsCommunity-Acquired InfectionsHospitalizationPneumonia030228 respiratory systemRisk factorsrisk factoranaerobicFemaleUnderweightmedicine.symptombusinessCardiology and Cardiovascular Medicine
researchProduct

Ventilatory associated barotrauma in COVID-19 patients: A multicenter observational case control study (COVI-MIX-study)

2022

Background The risk of barotrauma associated with different types of ventilatory support is unclear in COVID- 19 patients. The primary aim of this study was to evaluate the effect of the different respiratory support strategies on barotrauma occurrence; we also sought to determine the frequency of barotrauma and the clinical characteristics of the patients who experienced this complication. Methods This multicentre retrospective case-control study from 1 March 2020 to 28 February 2021 included COVID-19 patients who experienced barotrauma during hospital stay. They were matched with controls in a 1:1 ratio for the same admission period in the same ward of treatment. Univariable and multivari…

Pulmonary and Respiratory MedicineHigh flow nasal cannulaAcute respiratory failure; Barotrauma; COVID-19; High flow nasal cannula; Invasive mechanical ventilation; PneumothoraxBarotraumaCOVID-19PneumothoraxInvasive mechanical ventilationAcute respiratory failure
researchProduct

Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study

2016

BACKGROUND: Antibiotic resistance is a major global health problem and pathogens such as meticillin-resistant Staphylococcus aureus (MRSA) have become of particular concern in the management of lower respiratory tract infections. However, few data are available on the worldwide prevalence and risk factors for MRSA pneumonia. We aimed to determine the point prevalence of MRSA pneumonia and identify specific MRSA risk factors in community-dwelling patients hospitalised with pneumonia.METHODS: We did an international, multicentre study of community-dwelling, adult patients admitted to hospital with pneumonia who had microbiological tests taken within 24 h of presentation. We recruited investig…

Maleantibiotic resistancePrevalenceMRSAmedicine.disease_causepneumonia; antibiotic resistance; staphylococcus aureus; MRSAGlobal HealthCohort Studies0302 clinical medicineCommunity-acquired pneumoniaRisk FactorsRetrospective StudiePrevalenceCommunity-Acquired Infection030212 general & internal medicineeducation.field_of_studyCross InfectionRespiratory tract infectionsMethicillin-Resistant Staphylococcus aureuStaphylococcal InfectionsHospitalsCommunity-Acquired InfectionsInfectious DiseasesInfectious diseasesFemaleHumanMethicillin-Resistant Staphylococcus aureusstaphylococcus aureusmedicine.medical_specialtyPopulationAdmissionstaphylococcus aureuSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesHospitalInternal medicinemedicineHumanspneumoniaRisk factoreducationIntensive care medicineStaphylococcal InfectionRetrospective StudiesAgedbusiness.industryRisk FactorOdds ratioPneumoniamedicine.diseaseMethicillin-resistant Staphylococcus aureusPneumonia030228 respiratory systemMethicillin ResistanceCohort Studiebusiness
researchProduct

Effect of chest physiotherapy on cystic fibrosis sputum nanostructure: an experimental and theoretical approach.

2022

AbstractCystic fibrosis (CF) is a disease characterized by the production of viscous mucoid secretions in multiple organs, particularly the airways. The pathological increase of proteins, mucin and biological polymers determines their arrangement into a three-dimensional polymeric network, affecting the whole mucus and impairing the muco-ciliary clearance which promotes inflammation and bacterial infection. Thus, to improve the efficacy of the drugs usually applied in CF therapy (e.g., mucolytics, anti-inflammatory and antibiotics), an in-depth understanding of the mucus nanostructure is of utmost importance. Drug diffusivity inside a gel-like system depends on the ratio between the diffusi…

Low field NMRCystic FibrosisSputumPharmaceutical ScienceNanostructuresMucusSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoCystic fibrosiMesh size distributionDrug deliveryHumansCystic fibrosis; Drug delivery; Low field NMR; Mesh size distribution; Rheology; SputumRheologyPhysical Therapy ModalitiesDrug delivery and translational research
researchProduct

Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendation…

2020

An accurate knowledge of the epidemiology of community-acquired pneumonia (CAP) is key for selecting appropriate antimicrobial treatments. Very few etiological studies assessed the appropriateness of empiric guideline recommendations at a multinational level. This study aims at the following: (i) describing the bacterial etiologic distribution of CAP and (ii) assessing the appropriateness of the empirical treatment recommendations by clinical practice guidelines (CPGs) for CAP in light of the bacterial pathogens diagnosed as causative agents of CAP. Secondary analysis of the GLIMP, a point-prevalence international study which enrolled adults hospitalized with CAP in 2015. The analysis was l…

Male0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCommunity-acquired pneumonia030106 microbiologyAntimicrobial treatmentPrevalenceGuidelineSettore MED/10 - Malattie Dell'Apparato RespiratorioGuidelinesGlobal Healthmedicine.disease_causeImmunocompromised Host03 medical and health sciences0302 clinical medicineMedical microbiologyCommunity-acquired pneumoniaInternal medicineEpidemiologyStreptococcus pneumoniaePneumonia BacterialPrevalenceHumansMedicine030212 general & internal medicinePractice Patterns Physicians'AgedAged 80 and overbusiness.industryCorrectionGeneral MedicineGuidelineMiddle Agedmedicine.diseaseAnti-Bacterial AgentsCommunity-Acquired InfectionsHospitalizationPneumoniaInfectious DiseasesStreptococcus pneumoniaePractice Guidelines as TopicPseudomonas aeruginosaEtiologyOriginal ArticleFemaleGuideline Adherencebusiness
researchProduct

Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients

2018

Abstract Background The correct management of immunocompromised patients with pneumonia is debated. We evaluated the prevalence, risk factors, and characteristics of immunocompromised patients coming from the community with pneumonia. Methods We conducted a secondary analysis of an international, multicenter study enrolling adult patients coming from the community with pneumonia and hospitalized in 222 hospitals in 54 countries worldwide. Risk factors for immunocompromise included AIDS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplantation, chronic steroid use, and solid tumor. Results At least 1 risk factor for immunocompromis…

0301 basic medicineMalePediatricsEtiologyMultidrug-resistant pathogenMRSAPneumocystis pneumoniaPneumònia adquirida a la comunitatHOSPITALIZED-PATIENTS0302 clinical medicineCommunity-acquired pneumoniaRisk FactorsPrevalenceMedicine030212 general & internal medicinePNEUMOCYSTIS PNEUMONIAArticles and CommentariesAged 80 and overRespiratory tract infectionsAnemia AplasticMiddle Aged3. Good healthCommunity-Acquired InfectionsEuropeInfectious DiseasesImmunocompromise; Microbiology; MRSA; Multidrug-resistant pathogens; PneumoniaEtiologiaHematologic NeoplasmsFemaleBLOOD-STREAM INFECTIONSLung TransplantationMicrobiology (medical)medicine.medical_specialtyAsiaNeutropeniaCommunity-acquired pneumonia030106 microbiologyRESPIRATORY-TRACT INFECTIONSHematologic NeoplasmsSettore MED/10 - Malattie Dell'Apparato RespiratorioTRANSPLANT RECIPIENTSDISEASES-SOCIETYMicrobiology03 medical and health sciencesImmunocompromised HostPneumonia BacterialMANAGEMENTHumanspneumoniaBACTERIAL PNEUMONIAImmunocompromiseAgedAcquired Immunodeficiency Syndromebusiness.industrymicrobiologyBacterial pneumoniaAustraliaPneumoniamedicine.diseaseMultidrug-resistant pathogensPneumoniamultidrug-resistant pathogensMycosesBacteremiaAfricaEtiologyRISK-FACTORSimmunocompromiseAmericasbusinessClinical Infectious Diseases
researchProduct

Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course

2019

Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and Europea…

medicine.medical_specialtyantisynthetase antibodies; antisynthetase syndrome; arthritis; interstitial lung disease; myositisantisynthetase syndrome; antisynthetase antibodies; arthritis; myositis; interstitial lung diseaseMedizinArthritislcsh:MedicineAntisynthetase syndromeInterstitial lung diseaseAntisynthetase syndromeArticleNO03 medical and health sciences0302 clinical medicineInternal medicinemedicineantisynthetase antibodiesantisynthetase antibodies antisynthetase syndrome arthritis interstitial lung disease myositisddc:610Myositis030203 arthritis & rheumatologyinterstitial lung diseaseAntisynthetase antibodiesbiologyMyositisbusiness.industryArthritislcsh:RInterstitial lung diseaseAutoantibodyGeneral Medicinemedicine.diseasearthriti030228 respiratory systemarthritisTime courseCohortbiology.proteinAntibodyantisynthetase syndromebusinessantisynthetase antibodiemyositis
researchProduct